Posted by on Oct 23, 2016 in Defective Products | 0 comments

Just like other forms of cancer, breast cancer is treatable with chemotherapy. Recent advances in the medical field have made it possible to extend the chances of survival of a cancer patient. One of the most popular chemotherapy drug prescribed to cancer patients is taxotere. Approved by the US Food and Drug Administration in 1992, the drug generated more than $3 billion for Sanofi Aventis.

One of the common side effects of chemotherapy is hair loss. However, cancer survivors expect the hair to grow back within 3 – 6 months after stopping from treatment. A taxotere hair loss lawyer will tell you that the drug is associated with permanent hair loss which could last for over ten years. It is this side effect of Taxotere that has become the subject of recent lawsuits.

According to most of the claimant, the permanent hair loss that resulted from taking Taxotere caused them to experience a “disfiguring condition” which brought them mental anguish and economic damages. Most claims allege that Sanofi, the manufacturer of taxotere, deceived and misled them that just like other drugs, patients would see their hair grow back. The lawsuits also centered on the drug company’s fraudulent marketing scheme enticing physicians to use Taxotere.

To date, there has not been a recall of Taxotere. It was only in December 2015 that the FDA warned customers of the danger of permanent hair loss as a side effect of taxotere and updated the warning label. Part of the lawsuit is that the manufacturer of the drug did not inform patients of the side effects of the drug and that there were damages that resulted from the failure to inform.

Most lawsuits dwell on the profound impact on the well-being and quality of life that result from permanent hair loss. Studies have shown that hair loss was consistently one of the most troublesome side effects of taxotere and may affect body image.

Leave a Comment

Your email address will not be published. Required fields are marked *